Patents by Inventor Patricia Ibarra YON

Patricia Ibarra YON has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11931405
    Abstract: A bioconjugate of an E. coli glucosylated O4 antigen polysaccharide covalently linked to a carrier protein and compositions thereof are provided. Also provided are recombinant host cells for producing the bioconjugate, and methods of producing the bioconjugate using the recombinant host cells. The recombinant host cells contain a nucleic acid encoding a glucosyl transferase capable of modifying the E. coli O4 antigen with glucose branching to produce the glucosylated O4 antigen polysaccharide. Bioconjugates of an E. coli glucosylated O4 antigen polysaccharide described herein can be used alone or in combination with one or more additional E. coli O-antigen polysaccharides to induce antibodies against an E. coli glucosylated antigen, and to vaccinate a subject against extra-intestinal pathogenic E. coli (ExPEC).
    Type: Grant
    Filed: July 28, 2022
    Date of Patent: March 19, 2024
    Assignees: GlaxoSmithKline Biologicals S.A.
    Inventors: Jeroen Geurtsen, Jan Theunis Poolman, Kellen Cristhina Fae, Pieter Jan Burghout, Eveline Marleen Weerdenburg, Patricia Ibarra Yon, Darren Robert Abbanat, Stefan Jochen Kemmler, Michael Thomas Kowarik, Manuela Mally, Veronica Gambillara Fonck, Martin Edward Braun, Maria Paula Carranza Sandmeier
  • Publication number: 20230190926
    Abstract: Methods of producing bioconjugates of O-antigen polysaccharides covalently linked to a carrier protein using recombinant host cells are provided. The recombinant host cells used in the methods described herein encode a particular oligosaccharyl transferase enzyme depending on the O-antigen polysaccharide bioconjugate to be produced. The oligosaccharyl transferase enzymes can be PglB oligosaccharyl transferase or variants thereof. Also provided are compositions containing the bioconjugates, and methods of using the bioconjugates and compositions described herein to vaccinate a subject against extra-intestinal pathogenic E. coli. (ExPEC).
    Type: Application
    Filed: October 6, 2022
    Publication date: June 22, 2023
    Inventors: Jeroen GEURTSEN, Pieter Jan BURGHOUT, Eveline Marleen WEERDENBURG, Jan Theunis POOLMAN, Kellen Cristhina FAE, Patricia IBARRA YON, Darren Robert ABBANAT, Stefan Jochen KEMMLER, Michael Thomas KOWARIK, Manuela MALLY, Veronica GAMBILLARA FONCK, Martin Edward BRAUN, Maria Paula CARRANZA SANDMEIER
  • Publication number: 20230118878
    Abstract: A bioconjugate of an E. coli glucosylated O4 antigen polysaccharide covalently linked to a carrier protein and compositions thereof are provided. Also provided are recombinant host cells for producing the bioconjugate, and methods of producing the bioconjugate using the recombinant host cells. The recombinant host cells contain a nucleic acid encoding a glucosyl transferase capable of modifying the E. coli O4 antigen with glucose branching to produce the glucosylated O4 antigen polysaccharide. Bioconjugates of an E. coli glucosylated O4 antigen polysaccharide described herein can be used alone or in combination with one or more additional E. coli O-antigen polysaccharides to induce antibodies against an E. coli glucosylated antigen, and to vaccinate a subject against extra-intestinal pathogenic E. coli (ExPEC).
    Type: Application
    Filed: July 28, 2022
    Publication date: April 20, 2023
    Inventors: Jeroen GEURTSEN, Jan Theunis POOLMAN, Kellen Cristhina FAE, Pieter Jan BURGHOUT, Eveline Marleen WEERDENBURG, Patricia IBARRA YON, Darren Robert ABBANAT, Stefan Jochen KEMMLER, Michael Thomas KOWARIK, Manuela MALLY, Veronica GAMBILLARA FONCK, Martin Edward BRAUN, Maria Paula CARRANZA SANDMEIER
  • Publication number: 20230062987
    Abstract: Compositions and methods are described for inducing an immune response against extra-intestinal pathogenic Escherichia coli (ExPEC) to thereby provide immune protection against diseases associated with ExPEC. In particular, compositions and methods are described for using conjugates of E. coli polysaccharide antigens O25B, O1A, O2, and O6A covalently bound to a detoxified exotoxin A of Pseudomonas aeruginosa (EPA) carrier protein as vaccines for the prevention of invasive ExPEC disease caused by ExPEC serotypes O1A, O2, O6A and O25B.
    Type: Application
    Filed: September 23, 2022
    Publication date: March 2, 2023
    Inventors: Jan Theunis POOLMAN, Bert JACQUEMYN, Darren Robert ABBANAT, Patricia Ibarra YON, Peter Wilhelmus Maria HERMANS, Michael Thomas KOWARIK, Michael Lukas WETTER, Stefan Jochen KEMMLER, Micha Andres HÄUPTLE, Veronica Gambillara FONCK, Manuela MALLY
  • Patent number: 11491220
    Abstract: Methods of producing bioconjugates of O-antigen polysaccharides covalently linked to a carrier protein using recombinant host cells are provided. The recombinant host cells used in the methods described herein encode a particular oligosaccharyl transferase enzyme depending on the O-antigen polysaccharide bioconjugate to be produced. The oligosaccharyl transferase enzymes can be PglB oligosaccharyl transferase or variants thereof. Also provided are compositions containing the bioconjugates, and methods of using the bioconjugates and compositions described herein to vaccinate a subject against extra-intestinal pathogenic E. coli. (ExPEC).
    Type: Grant
    Filed: March 18, 2020
    Date of Patent: November 8, 2022
    Assignees: Janssen Pharmaceuticals, Inc.
    Inventors: Jeroen Geurtsen, Pieter Jan Burghout, Eveline Marleen Weerdenburg, Jan Theunis Poolman, Kellen Cristhina Fae, Patricia Ibarra Yon, Darren Robert Abbanat, Stefan Jochen Kemmler, Michael Thomas Kowarik, Manuela Mally, Veronica Gambillara Fonck, Martin Edward Braun, Maria Paula Carranza Sandmeier
  • Patent number: 11484582
    Abstract: Compositions and methods are described for inducing an immune response against extra-intestinal pathogenic Escherichia coli (ExPEC) to thereby provide immune protection against diseases associated with ExPEC. In particular, compositions and methods are described for using conjugates of E. coli polysaccharide antigens O25B, O1A, O2, and O6A covalently bound to a detoxified exotoxin A of Pseudomonas aeruginosa (EPA) carrier protein as vaccines for the prevention of invasive ExPEC disease caused by ExPEC serotypes O1A, O2, O6A and O25B.
    Type: Grant
    Filed: February 4, 2020
    Date of Patent: November 1, 2022
    Assignees: Janssen Pharmaceuticals, Inc.
    Inventors: Jan Theunis Poolman, Bert Jacquemyn, Darren Robert Abbanat, Patricia Ibarra Yon, Peter Wilhelmus Maria Hermans, Michael Thomas Kowarik, Michael Lukas Wetter, Stefan Jochen Kemmler, Micha Andres Häuptle, Veronica Gambillara Fonck, Manuela Mally
  • Patent number: 11446370
    Abstract: A bioconjugate of an E. coli glucosylated O4 antigen polysaccharide covalently linked to a carrier protein and compositions thereof are provided. Also provided are recombinant host cells for producing the bioconjugate, and methods of producing the bioconjugate using the recombinant host cells. The recombinant host cells contain a nucleic acid encoding a glucosyl transferase capable of modifying the E. coli O4 antigen with glucose branching to produce the glucosylated O4 antigen polysaccharide. Bioconjugates of an E. coli glucosylated O4 antigen polysaccharide described herein can be used alone or in combination with one or more additional E. coli O-antigen polysaccharides to induce antibodies against an E. coli glucosylated antigen, and to vaccinate a subject against extra-intestinal pathogenic E. coli (ExPEC).
    Type: Grant
    Filed: March 18, 2020
    Date of Patent: September 20, 2022
    Assignees: Janssen Pharmaceuticals, Inc., GlaxoSmithKline Biologicals S.A.
    Inventors: Jeroen Geurtsen, Jan Theunis Poolman, Kellen Cristhina Fae, Pieter Jan Burghout, Eveline Marleen Weerdenburg, Patricia Ibarra Yon, Darren Robert Abbanat, Stefan Jochen Kemmler, Michael Thomas Kowarik, Manuela Mally, Veronica Gambillara Fonck, Martin Edward Braun, Maria Paula Carranza Sandmeier
  • Publication number: 20210046171
    Abstract: Compositions and methods are described for inducing an immune response against extra-intestinal pathogenic Escherichia coli (ExPEC) to thereby provide immune protection against diseases associated with ExPEC. In particular, compositions and methods are described for using conjugates of E. coli polysaccharide antigens O25B, O1A, O2, and O6A covalently bound to a detoxified exotoxin A of Pseudomonas aeruginosa (EPA) carrier protein as vaccines for the prevention of invasive ExPEC disease caused by ExPEC serotypes O1A, O2, O6A and O25B.
    Type: Application
    Filed: February 4, 2020
    Publication date: February 18, 2021
    Inventors: Jan Theunis POOLMAN, Bert JACQUEMYN, Darren Robert ABBANAT, Patricia Ibarra YON, Peter Wilhelmus Maria HERMANS, Michael Thomas KOWARIK, Michael Lukas WETTER, Stefan Jochen KEMMLER, Micha Andres HÄUPTLE, Veronica Gambillara FONCK, Manuela MALLY
  • Publication number: 20200353073
    Abstract: Methods of producing bioconjugates of O-antigen polysaccharides covalently linked to a carrier protein using recombinant host cells are provided. The recombinant host cells used in the methods described herein encode a particular oligosaccharyl transferase enzyme depending on the O-antigen polysaccharide bioconjugate to be produced. The oligosaccharyl transferase enzymes can be PglB oligosaccharyl transferase or variants thereof. Also provided are compositions containing the bioconjugates, and methods of using the bioconjugates and compositions described herein to vaccinate a subject against extra-intestinal pathogenic E. coli. (ExPEC).
    Type: Application
    Filed: March 18, 2020
    Publication date: November 12, 2020
    Inventors: Jeroen GEURTSEN, Pieter Jan BURGHOUT, Eveline Marleen WEERDENBURG, Jan Theunis POOLMAN, Kellen Cristhina FAE, Patricia IBARRA YON, Darren Robert ABBANAT, Stefan Jochen KEMMLER, Michael Thomas KOWARIK, Manuela MALLY, Veronica GAMBILLARA FONCK, Martin Edward BRAUN, Maria Paula CARRANZA SANDMEIER
  • Publication number: 20200316184
    Abstract: A bioconjugate of an E. coli glucosylated O4 antigen polysaccharide covalently linked to a carrier protein and compositions thereof are provided. Also provided are recombinant host cells for producing the bioconjugate, and methods of producing the bioconjugate using the recombinant host cells. The recombinant host cells contain a nucleic acid encoding a glucosyl transferase capable of modifying the E. coli O4 antigen with glucose branching to produce the glucosylated O4 antigen polysaccharide. Bioconjugates of an E. coli glucosylated O4 antigen polysaccharide described herein can be used alone or in combination with one or more additional E. coli O-antigen polysaccharides to induce antibodies against an E. coli glucosylated antigen, and to vaccinate a subject against extra-intestinal pathogenic E. coli (ExPEC).
    Type: Application
    Filed: March 18, 2020
    Publication date: October 8, 2020
    Inventors: Jeroen GEURTSEN, Jan Theunis POOLMAN, Kellen Cristhina FAE, Pieter Jan BURGHOUT, Eveline Marleen WEERDENBURG, Patricia IBARRA YON, Darren Robert ABBANAT, Stefan Jochen KEMMLER, Michael Thomas KOWARIK, Manuela MALLY, Veronica GAMBILLARA FONCK, Martin Edward BRAUN, Maria Paula CARRANZA SANDMEIER
  • Patent number: 10583185
    Abstract: Compositions and methods are described for inducing an immune response against extra-intestinal pathogenic Escherichia coli (ExPEC) to thereby provide immune protection against diseases associated with ExPEC. In particular, compositions and methods are described for using conjugates of E. coli polysaccharide antigens O25B, O1A, O2, and O6A covalently bound to a detoxified exotoxin A of Pseudomonas aeruginosa (EPA) carrier protein as vaccines for the prevention of invasive ExPEC disease caused by ExPEC serotypes O1A, O2, O6A and O25B.
    Type: Grant
    Filed: August 24, 2016
    Date of Patent: March 10, 2020
    Assignees: GlaxoSmithKline Biological S.A., Janssen Pharmaceuticals, Inc.
    Inventors: Jan Theunis Poolman, Bert Jacquemyn, Darren Robert Abbanat, Patricia Ibarra Yon, Peter Wilhelmus Maria Hermans, Michael Thomas Kowarik, Michael Lukas Wetter, Stefan Jochen Kemmler, Micha Andres Häuptle, Veronica Gambillara Fonck, Manuela Mally
  • Publication number: 20180243393
    Abstract: Compositions and methods are described for inducing an immune response against extra-intestinal pathogenic Escherichia coli (ExPEC) to thereby provide immune protection against diseases associated with ExPEC. In particular, compositions and methods are described for using conjugates of E. coli polysaccharide antigens O25B, O1A, O2, and O6A covalently bound to a detoxified exotoxin A of Pseudomonas aeruginosa (EPA) carrier protein as vaccines for the prevention of invasive ExPEC disease caused by ExPEC serotypes O1A, O2, O6A and O25B.
    Type: Application
    Filed: August 24, 2016
    Publication date: August 30, 2018
    Inventors: Jan Theunis POOLMAN, Bert JACQUEMYN, Darren Robert ABBANAT, Patricia Ibarra YON, Peter Wilhelmus Maria HERMANS, Michael Thomas KOWARIK, Michael Lukas WETTER, Stefan Jochen KEMMLER, Micha Andres HÄUPTLE, Veronica GAMBILLARA FONCK, Manuela MALLY